Clinical trial
A Phase I/II Study of Sunitinib Malate (SU011248) In The Treatment of Patients With Malignant Gastrointestinal Stromal Tumor (GIST) Previously Treated by Imatinib Mesylate.
NCT00457743 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study of Sunitinib Malate (SU011248) In The Treatment of Patients With Malignant Gastrointestinal Stromal Tumor (GIST) Previously Treated by Imatinib Mesylate.
- Lead sponsor
- Pfizer
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- January 31, 2005
- Completion date
- August 31, 2008
- Enrollment
- 36 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.